Drug dosage individualization based on a random-effects linear lodel

Journal of Biopharmaceutical Statistics

Volumn 22, Issue 3, 2012, Pages 463-484

  Diaz, Francisco J ^a   Cogollo, Myladis R ^b   Spina, Edoardo ^c   Santoro, Vincenza ^c   Rendon, Diego M ^d   De Leon, Jose ^e  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD EAFIT   (Colombia)

^c UNIVERSITY OF MESSINA   (Italy)

^d Financial Analysis Unit   (Colombia)

^e Mental Health Research Center   (United States)

Author keywords

Bayes' theorem; Bayesian feedback; Clozapine; Decision theory; Drug dosage individualization; Personalized medicine; Population pharmacokinetics; Random effects linear models; Therapeutic drug monitoring; Therapeutic window

Indexed keywords

CLOZAPINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PHENOBARBITAL; VALPROIC ACID;

ALGORITHM; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; COMPUTER SIMULATION; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG MONITORING; HUMAN; INDIVIDUALIZATION; OPTIMAL DRUG DOSE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; STATISTICAL MODEL; STEADY STATE;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDIVIDUALIZED MEDICINE; LINEAR MODELS; PHARMACEUTICAL PREPARATIONS; RANDOM ALLOCATION;

EID: 84859191400     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2010.547264     Document Type: Article

References (24)

1. Botts, S., Diaz, F. J., Santoro, V., Spina, E., Muscatello, M. R., Cogollo, M., Castro, F. E., de Leon, J. (2008). Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32:1453-1458.
2. Cuadrado, M. J., Khamashta, M. A. (2000). The anti-phospholipid antibody syndrome (Hughes syndrome): Therapeutic aspects. Bailliere's Clinical Rheumatology 14:151-163.
3. de Leon, J., Susce, M. T., Johnson, M., Hardin, M., Pointer, L., Ruao, G., Diaz, F. J. (2007a). A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Research 92:95-102.
4. de Leon, J., Susce, M. T., Pan, R. M., Wedlund, P. J., Orrego, M. L., Diaz, F. J. (2007b). A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40:93-102.
5. Diaz, F. J., Rivera, T. E., Josiassen, R. C., de Leon, J. (2007). Individualizing drug dosage by using a random intercept linear model. Statistics in Medicine 26:2052-2073.
6. Diaz, F. J., Santoro, V., Spina, E., Cogollo, M., Rivera, T. E., Botts, S., de Leon, J. (2008). Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 41:81-91.
7. Dole, V. P. (1980). Addictive behavior. Scientific American 243(6):138-154.
8. Hu, C., Zhou, H. (2008). An improved approach for confirmatory phase III population pharmacokinetic analysis. Journal of Clinical Pharmacology 48:812-822.
9. Hu, C., Zhang, J., Zhou, H. (2009). Confirmatory analysis for phase III population pharmacokinetics. Pharmaceutical Statistics (www.interscience.wiley. com). doi: 10.1002/pst.403.
10. Jiao, Z., Shi, X. J., Li, Z. D., Zhong, M. K. (2009). Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. British Journal of Clinical Pharmacology 68:47-60.
11. Littell, R. C., Milliken, G. A., Stroup, W. W., Wolfinger, R. D. (2006). SAS for Mixed Models, 2nd ed. Cary, NC: SAS Institute, Inc.
12. Molenberghs, G., Burzykowski, T., Alonso, A., Assam, P., Tilahun, A., Buyse, M. (2008). The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. Journal of Statistical Planning and Inference 138:432-449.
13. Muñoz, A., Xu, J. (1996). Models for the incubation of AIDS and variations according to age and period. Statistics in Medicine 15:2459-2473.
14. Nies, A. S. (2001). Principles of therapeutics. In: Hardman, J. G., Limbird, L. E., Gilman, A. G., eds. The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill.
15. Pillai, G., Mentré, F., Steimer, J.-L. (2005). Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. Journal of Pharmacokinetics and Pharmacodynamics 32:161-183.
16. Sabaawi, M., Singh, N. N., de Leon, J. (2006). Guidelines for the use of clozapine in individuals with developmental disabilities. Research in Developmental Disabilities 27:309-336.
17. SAS Institute, Inc. (2008). SAS/IML 9.2 User's Guide. Cary, NC: SAS Institute, Inc.
18. Sheiner, L. B., Beal, S. L. (1980). Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: Routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 8:553-571.
19. Sheiner, L. B., Beal, S. L. (1982). Bayesian individualization of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods. Journal of Pharmaceutical Sciences 71:1344-1348.
20. Shirrell, D. J., Gibbar-Clements, T., Dooley, R., Free, C. (1999). Understanding therapeutic drug monitoring. American Journal of Nursing 99:42-44.
21. Verbeke, G., Molenberghs, G. (2000). Linear Mixed Models for Longitudinal Data. New York, NY: Springer-Verlag.
22. Vozeh, S., Muir, K. T., Sheiner, L. B., Follath, F. (1981). Predicting individual phenytoin dosage. Journal of Pharmacokinetics and Biopharmaceutics 9:131-146.
23. Whiting, B., Kelman, A. W., Grevel, J. (1986). Population pharmacokinetics. Theory and clinical application. Clinical Pharmacokinetics 11:387-401.
24. Winter, M. E. (2004). Basic Clinical Pharmacokinetics, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins.